Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Cannabis
|
| gptkbp:aroma |
odorless
|
| gptkbp:biosynthesized_from |
from cannabigerolic acid (CBGA)
|
| gptkbp:boilingPoint |
175–178 °C
|
| gptkbp:CASNumber |
5957-75-5
|
| gptkbp:chemicalFormula |
C21H30O2
|
| gptkbp:color |
colorless to pale amber solid
|
| gptkbp:DEAStatus |
Schedule I (if synthetic, US federal)
|
| gptkbp:eliminationHalfLife |
unknown
|
| gptkbp:excretion |
urine
|
| gptkbp:FDAWarning |
not evaluated for safety or efficacy
|
| gptkbp:firstIsolatedFrom |
1941
|
| gptkbp:firstSynthesized |
gptkb:Roger_Adams
|
| gptkbp:flavor |
slightly bitter
|
| gptkbp:foundIn |
Cannabis
|
| https://www.w3.org/2000/01/rdf-schema#label |
delta-8-THC
|
| gptkbp:isomerOf |
delta-9-THC
|
| gptkbp:IUPACName |
gptkb:(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
|
| gptkbp:legalStatus |
varies by country and US state
|
| gptkbp:marketedAs |
hemp-derived product
legal alternative to delta-9-THC |
| gptkbp:meltingPoint |
63–66 °C
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
314.464 g/mol
|
| gptkbp:otherName |
gptkb:Δ8-THC
delta-8-tetrahydrocannabinol Δ8-tetrahydrocannabinol |
| gptkbp:produces |
red eyes
altered perception dry mouth appetite stimulation mild euphoria anxiety (rare) |
| gptkbp:psychoactive |
true
|
| gptkbp:relatedTo |
gptkb:THCV
gptkb:CBD gptkb:CBN delta-9-THC |
| gptkbp:riskFactor |
contaminants in unregulated products
possible psychoactive impairment unknown long-term effects |
| gptkbp:routeOfAdministration |
oral
inhalation sublingual |
| gptkbp:solubility |
lipid-soluble
|
| gptkbp:source |
can be synthesized from CBD
minor constituent in cannabis |
| gptkbp:usedFor |
recreational purposes
potential medical uses |
| gptkbp:bfsParent |
gptkb:tetrahydrocannabinol
|
| gptkbp:bfsLayer |
7
|